CorMedix Inc. (AMEX:CRMD) will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.cormedix.com
Earnings Expectation
CorMedix Inc. biopharmaceutical firm, is reporting second quarter earnings results on Monday 10th August 2020, after market close. The consensus estimates from Thomson Reuters are loss of $ 0.14 per share. For the full year, analysts predict revenues of $ 2.69 million, while looking forward to loss of $ 0.88 per share.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc.
